A tidy update on Hellenic’s timescale to roll out their flowers to the German market. Kanabo have a £750k stake in the company.
4 Likes
I’m not really sure what has caused the bump in the last few days but I like it.
4 Likes
An excellent rally today, any idea on the cause?
4 Likes
Not sure what has caused this sudden spike. However i wish it goes all the way to 50p. 
3 Likes
If there has been any news from Kanabo, I’ve missed it. Likely, there will be others reading with a wry, knowing smile, but their are some signs, that show a change in mood towards cannabinoids
A race to legalisation in
Germany
Switzerland
Czech Republic
A lot of companies jostling for space in europe
A race to get ahead of the game in terms of medical cannabis research
UK have openly stated they want to lead the way. But unlikely given our current Home Secretary
Other reasons I do not know about are also likely. It will be a bumpy road (see Home Secretary).
1 Like
Well that didn’t last long wondering if I should just jump ship or if it’s worth the risk long term.
1 Like
It is frustrating, but this is going to be an epic journey to the top rather than shortcut. I got in at 6p and have been averaging down. Kanabo will require patience.
But, and it is a positive but, things are happening. And in particular when it comes to medical use of cannibinoids. The NHS reimbursed cannabinoid prescriptions for the first time ever last month. I have also included a link to another legislative milestone below (not kanabo - but what is good for the goose). Last year was horrible but the correction was coming after the crazed excitement about cannabis stocks the previous year.
This year, there should be a lot more news about legislation across europe and america. This will help investors actually firm up their estimate of the size of the industry. Elements of it will continue to be frustrating, but there is too much common sense in our knowledge of the use of cannibinoids for Daily Mail type headlines to hold any sway. And par example
3 Likes
A new platform that will help GPs and patients overcome challenges and misconceptions around prescribing cannabis
2 Likes
That sounds very positive its very difficult to get hold off currently even on a private prescription x
1 Like
A review of the recent Kanabo jump in price and some thoughts on what is next for the company
1 Like
The below article is interesting to read in the context of the uneven coverage regarding legislation around cannabis. One day a major press outlet will focus on the medical benefits of cannabinoids, whilst the following day they will outline legislation as act of saving the youth from the terror of cannabinoids (quite a mess in the press!).
So, it is encouraging to see a PR firm with experience in emerging markets starting work on solidifying the message. Which at the very least will save us from the Home Secretary and other intellectual rigours born in the mid half of the twentieth century
Kanabo’s review of 2022 highlights and their focus for 2023, including an update on the CE mark approval.
1 Like
The positive flurry about the move towards legislation europe continues. And some more evidence that research of the health benefits of cannibis is starting to look like a race! Its very encouraging but in this area of investing it pays not to get too excited. The article, however, does bode well for Kanabo and the prospect of a CE mark which means their new product (planned for the end of this year) will be deemed to be safe to be sold on the continent.
2 Likes
More positive news on the progressive approach to prescribing medical cannibis treatments. In particular considering the current UK government take a ‘fear first’ approach to medical cannabis research. Added to the recent £1.5m news of funding for Edinburgh Uni. Cannibis stocks are a bit of a white knuckle ride at present but I hope this momentum of rational thinking leads up to Kanabo securing that CE mark approval - maybe Q3.
2 Likes
Good news from Kanabo on their GP service
Link to the site
1 Like
An insight into the use of cannabis as a treatment for chronic. Also includes some alarming stats around the reliance on the illegal trade of cannabis, positioning the case for a well regulated market and infrastructure. If only there was a company that was offering such a service…
1 Like
Times article on Treat it, Kanabo’s recently launched GP platform
1 Like
An update on Germany’s review of their approach to prescribing medicinal cannabis. Im summary, the recommendations if out into law will de stigmatise prescriptive process for medical cannabis and in some instances remove entirely the process, naturally benefiting the patient. In terms of how this relates to Kanabo: the ce mark approval if passed eill mean Kanabo will have access to the German medicinal cannabis market.
An overview of an article on the positive impact of medical cannabis on treating neuropathic pain. The article underlines not only the benefits of treating pain with cannabinoids but also shows how more research accessing cannabis will help us better understand pain and treatment options.
1 Like
Thanks for your updates Chris… Much appreciated 
1 Like